Publications by authors named "I Charreau"
Article Synopsis
- - The study examined cytomegalovirus (CMV) risk factors in men who have sex with men, focusing on participants in the HIV pre-exposure prophylaxis trial IPERGAY-ANRS.
- - Of the 417 participants, 382 were already CMV positive, showing a high prevalence rate of 91.6%, and 10 new cases were identified during the study.
- - Findings suggest that having many sexual partners increases the likelihood of CMV, with shedding observed in participants who seroconverted.
Article Synopsis
- A study assessed the prevalence and risk factors of Human Herpesvirus-8 (HHV-8) infection among HIV-negative men who have sex with men (MSM) taking pre-exposure prophylaxis (PrEP) in France and Canada, finding a 24% seroprevalence at the start and an incidence rate of 2.66 per 100 person-years.
- Key risk factors for seropositivity included older age, a high number of sexual partners, use of chemsex, and HSV-2 positivity.
- Among those already infected, 32% showed HHV-8 in saliva, highlighting the potential for oral transmission of the virus in this group.
Article Synopsis
- The study focused on the prevalence and incidence of hepatitis E virus (HEV) among men who have sex with men (MSM) in a trial for pre-exposure prophylaxis (PrEP).
- Out of 416 MSM participants, 14.9% tested positive for HEV at the start, with only older age being a significant factor linked to positivity.
- The overall incidence rate for new HEV infections over an average follow-up of 2.1 years was low at 1.19% per 100 person-years, suggesting that sexual transmission is not a major concern for HEV in this group, unlike hepatitis A virus (HAV).
Article Synopsis
- Vaccination against hepatitis A (HAV) and hepatitis B (HBV) is strongly recommended for men who have sex with men (MSM), with a study evaluating vaccine uptake during the ANRS IPERGAY pre-exposure prophylaxis (PrEP) trial.
- Out of 427 MSM participants analyzed, a significant number were non-immune to HAV (50.4%), with high vaccination uptake: 96.1% received at least one dose of HAV vaccine, and 97.6% of HBV non-immune participants received at least one HBV vaccine dose.
- Overall, complete vaccination resulted in a high rate of immunity, showing that PrEP visits are crucial for offering vaccination to at-risk MSM who are
Objective: High rates of sexually transmitted infections (STIs) have been reported among pre-exposure prophylaxis (PrEP) users. We wished to assess the incidence and risk factors for recurrent STIs.
Design: The ANRS IPERGAY trial was a prospective study investigating PrEP among MSM and transgender women in outpatient clinics in France and Canada.